A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0

作者：

Kelly, William Kevin ^{[1
]}

Hussain, Arif ^{[2
]}

Saraiya, iren ^{[3
]}

Thanigaimani, Pradeep ^{[4
]}

Sun, Furong

Seebach, Frank A.

Lawy, Israel

Sandigursky, Sabina

Miller, Elizabeth

机构：

[1] Thomas Jefferson Univ, Philadelphia, PA USA

[2] Univ Maryland, Med Ctr, Baltimore, MD USA

[3] Rutgers State Universityof New Jersey, Canc Inst New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA

[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 6_SUPPL期

关键词：

283-2494-5577-2829; 613-225-325; 261-566-9263; 283-224-11611-3642-3956; 283-197-6219; 613-225-2782; 261-492-3532-9726; 6; 5; 4; 3; 2; 60; 1; 38092-22583;

D O I：

10.1200/JCO.2023.41.6_suppl.TPS282

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS282

引用

页码：TPS282 / TPS282

页数：1

共 50 条

[41] Second-Line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC) An international, randomized, open-label, Phase 3 Study of the PARP Inhibitor Rucaparib versus Physicians Choice of Treatment for Patients with metastatic castration-resistant Prostate Cancer (mCRPC) associated with homologous Recombination Deficiency (TRITON3) - AP 100/18 of the AUO
Rexer, H.
Graefen, M.
Merseburger, A.
AKTUELLE UROLOGIE, 2019, 50 (05) : 478 - 479
[42] VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Sartor, A. Oliver
Morris, Michael J.
Krause, Bernd J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Sartor, A. Oliver
Morris, Michael J.
Messman, Richard
Krause, Bernd J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[44] Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.
De Bono, Johann S.
Chowdhury, Simon
Feyerabend, Susan
Elliott, Tony
Grande, Enrique
Melhem-Bertrandt, Amal
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[45] TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Ryan, Charles J.
Abida, Wassim
Bryce, Alan Haruo
Balar, Arjun Vasant
Dumbadze, Igor
Given, Robert W.
Morris, David
Petrylak, Daniel Peter
Redfern, Charles H.
Scher, Howard I.
Watkins, Simon Paul
Simmons, Andrew
Passler, Luke
Golsorkhi, Tony
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[46] Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Mateo, Joaquin
Porta, Nuria
Bianchini, Diletta
McGovern, Ursula
Elliott, Tony
Jones, Robert
Syndikus, Isabel
Ralph, Christy
Jain, Suneil
Varughese, Mohini
Parikh, Omi
Crabb, Simon
Robinson, Angus
McLaren, Duncan
Birtle, Alison
Tanguay, Jacob
Miranda, Susana
Figueiredo, Ines
Seed, George
Bertan, Claudia
Flohr, Penny
Ebbs, Berni
Rescigno, Pasquale
Fowler, Gemma
Ferreira, Ana
Riisnaes, Ruth
Pereira, Rita
Curcean, Andra
Chandler, Robert
Clarke, Matthew
Gurel, Bora
Crespo, Mateus
Rodrigues, Daniel Nava
Sandhu, Shahneen
Espinasse, Aude
Chatfield, Peter
Tunariu, Nina
Yuan, Wei
Hall, Emma
Carreira, Suzanne
de Bono, Johann S.
LANCET ONCOLOGY, 2020, 21 (01): : 162 - 174
[47] A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Abida, Wassim
Bradley, Thomas Paul
Rezazadeh, Arash
Karsh, Lawrence Ivan
Ross, Ashley
Saltzstein, Daniel
Argon, Evren Kocabas
Hamlett, Anthony
Tang, Jeanie
Adib, Deyaa
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[48] PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Petrylak, Daniel P.
Vogelzang, Nicholas J.
Chatta, Kamal
Fleming, Mark T.
Smith, David C.
Appleman, Leonard J.
Hussain, Arif
Modiano, Manuel
Singh, Parminder
Tagawa, Scott T.
Gore, Ira
McClay, Edward F.
Mega, Anthony E.
Sartor, A. Oliver
Somer, Bradley
Wadlow, Raymond
Shore, Neal D.
Olson, William C.
Stambler, Nancy
DiPippo, Vincent A.
Israel, Robert J.
PROSTATE, 2020, 80 (01): : 99 - 108
[49] An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (CheckMate 9KD)
Gruellich, C.
Fizazi, K.
Drake, C.
Shaffer, D.
Pachynski, R.
Saad, F.
Ciprotti, M.
Kong, G.
Ryan, C.
Petrylak, D.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 323 - 323
[50] A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Agarwal, Neeraj
Azad, Arun
Carles, Joan
Chowdhury, Simon
McGregor, Bradley
Merseburger, Axel S.
Oudard, Stephane
Saad, Fred
Soares, Andrey
Benzaghou, Fawzi
Kerloeguen, Yannick
Kimura, Akiko
Mohamed, Nehal
Panneerselvam, Ashok
Wang, Fong
Pal, Sumanta
FUTURE ONCOLOGY, 2022, 18 (10) : 1185 - 1198

← 1 2 3 4 5 →